Vasileios Georgoulis

Mr. Vasileios Georgoulis

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 June 2023 in Biology
Verified
Journal Article
Open access
PDF file
VGVasileios Georgoulis
Vasileios Georgoulis
APAlexanndra Papoudou-Bai
Alexanndra Papoudou-Bai
AMAlexandros Makis
Alexandros Makis
PKPanagiotis Kanavaros
Panagiotis Kanavaros
Eleftheria HatzimichaelEleftheria Hatzimichael
Eleftheria Hatzimichael
Classic Hodgkin lymphoma (cHL) is a lymphoid neoplasm composed of rare neoplastic Hodgkin and Reed–Sternberg (HRS) cells surrounded by a reactive tumor microenvironment (TME) with suppressive properties against anti-tumor immunity. TME is mainly composed of T cells (CD4 helper, CD8 cytotoxic and regulatory) and tumor-associated macrophages (TAMs), but the impact of these cells on the natural course of the disease is not absolutely understood. TME contributes to the immune evasion of neoplastic HRS cells through the production of various cytokines and/or the aberrant expression of immune checkpoint molecules in ways that have not been fully understood yet. Herein, we present a comprehensive review of findings regarding the cellular components and the molecular features of the immune TME in cHL, its correlation with treatment response and prognosis, as well as the potential targeting of the TME with novel therapies. Among all cells, macrophages appear to be a most appealing target for immunomodulatory therapies, based on their functional plasticity and antitumor potency.

21 November 2024 in Biomedicines
Verified
Journal Article
Open access
PDF file
AKAndreas Epameinondas Koumpis
Andreas Epameinondas Koumpis
VGVasileios Georgoulis
Vasileios Georgoulis
KPKonstantina Papathanasiou
Konstantina Papathanasiou
APAlexanndra Papoudou-Bai
Alexanndra Papoudou-Bai
PKPanagiotis Kanavaros
Panagiotis Kanavaros
Eleftheria HatzimichaelEleftheria Hatzimichael
Eleftheria Hatzimichael
Diffuse Large B-cell Lymphoma (DLBCL) is the most common aggressive non-Hodgkin lymphoma (NHL). Despite the use of newer agents, such as polatuzumab vedotin, more than one-third of patients have ultimately relapsed or experienced refractory disease. MiRNAs are single-stranded, ~22-nucleotide-long RNAs that interact with their target RNA. They are significant regulators of post-transcriptional gene expression. One significant miRNA, miR-155, is involved in the pathophysiology of DLBCL and it is a critical modulator of hematopoiesis, inflammation, and immune responses. Targets of miR-155, such as histone deacetylase 4 (HDAC4), suppressor of cytokine signaling-1 (SOCS1) and immune cells, play a crucial role in DLBCL pathogenesis, since miR-155 regulates key pathways, transcription factors and cytokine expression and shapes the tumor microenvironment in DLBCL. In this review, we examine the role of miR-155 in DLBCL and its potential as a future diagnostic, prognostic, or predictive biomarker.

17 May 2023 in Preprints.org
Verified
Preprint
Open access
PDF file
VGVasileios Georgoulis
Vasileios Georgoulis
APAlexanndra Papoudou-Bai
Alexanndra Papoudou-Bai
AMAlexandros Makis
Alexandros Makis
PKPanagiotis Kanavaros
Panagiotis Kanavaros
Eleftheria HatzimichaelEleftheria Hatzimichael
Eleftheria Hatzimichael
Classic Hodgkin lymphoma (cHL) is a lymphoid neoplasm composed of rare neoplastic Hodgkin and Reed-Sternberg (HRS) cells surrounded by a reactive tumor microenvironment (TME) with suppressive properties against anti-tumor immunity. TME is mainly composed of T-cells (CD4 helper, CD8 cytotoxic and regulatory), and tumor-associated macrophages (TAMs) but the impact of these cells on the natural course of the disease is not absolutely understood. TME contributes to the immune evasion of neoplastic HRS cells through production of various cytokines and/or aberrant expression of immune checkpoint molecules, in ways that have not been fully understood yet. Herein, we present a comprehensive review of findings regarding the cellular components and the molecular features of the immune TME in cHL, its correlation with treatment response and prognosis as well as the potential targeting of the TME with novel therapies. Among all cells, macrophages appear to be a most appealing target for immunomodulatory therapies, based on their functional plasticity and antitumor potency.

30 September 2023 in Cancers
Verified
Journal Article
Open access
PDF file
VGVasileios Georgoulis
Vasileios Georgoulis
AKAndreas Epameinondas Koumpis
Andreas Epameinondas Koumpis
Eleftheria HatzimichaelEleftheria Hatzimichael
Eleftheria Hatzimichael
Myelodysplastic syndromes or neoplasms (MDS) are a heterogeneous group of myeloid clonal disorders characterized by peripheral blood cytopenias, blood and marrow cell dysplasia, and increased risk of evolution to acute myeloid leukemia (AML). Non-coding RNAs, especially microRNAs and long non-coding RNAs, serve as regulators of normal and malignant hematopoiesis and have been implicated in carcinogenesis. This review presents a comprehensive summary of the biology and role of non-coding RNAs, including the less studied circRNA, siRNA, piRNA, and snoRNA as potential prognostic and/or predictive biomarkers or therapeutic targets in MDS.

9 September 2025 in Diseases
Verified
Journal Article
Open access
PDF file
EAElisavet Apostolidou
Elisavet Apostolidou
VGVasileios Georgoulis
Vasileios Georgoulis
DLDimitrios Leonardos
Dimitrios Leonardos
EKEleni D. Kapsali
Eleni D. Kapsali
Eleftheria HatzimichaelEleftheria Hatzimichael
Eleftheria Hatzimichael
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired clonal hematologic disorder caused by somatic mutations in the PIGA gene of hematopoietic stem cells, leading to the absence of GPI-anchored proteins, including the complement regulators CD55 and CD59. This deficiency results in uncontrolled complement activation, causing intravascular and extravascular hemolysis, thrombosis, and bone marrow failure. Historically associated with substantial morbidity, PNH management has been transformed by the advent of complement inhibitors. Eculizumab, the first approved C5 inhibitor, significantly reduced thrombotic risk and improved survival but did not eliminate anemia due to extravascular hemolysis. Newer agents now target proximal complement components, offering broader control and improved convenience. This review summarizes the pathophysiology of PNH, evaluates established and emerging complement inhibitors, and discusses ongoing therapeutic challenges and future directions.

30 January 2026 in Diseases
Verified
Journal Article
Open access
PDF file
EAElisavet Apostolidou
Elisavet Apostolidou
VGVasileios Georgoulis
Vasileios Georgoulis
DLDimitrios Leonardos
Dimitrios Leonardos
LBLEONIDAS BENETATOS
LEONIDAS BENETATOS
EKEleni D. Kapsali
Eleni D. Kapsali
Eleftheria HatzimichaelEleftheria Hatzimichael
Eleftheria Hatzimichael
Acute myeloid leukemia (AML) continues to pose significant therapeutic challenges, with high relapse rates driven largely by leukemic stem cells (LSCs), a rare, therapy-resistant population with self-renewal capacity, niche adaptation, and the ability to re-initiate disease. In this state-of-the-art review, we synthesize recent advances in LSC biology, addressing (i) how LSCs differ functionally and phenotypically from normal hematopoietic stem cells (HSCs), (ii) practical approaches for LSC quantification using multiparameter flow cytometry and LSC-enriched marker panels, (iii) the dysregulated signaling, metabolic and epigenetic programs that enable LSC persistence under chemotherapy and contribute to measurable residual disease, and (iv) current therapeutic strategies targeting LSC eradication, including antibody-based therapies, apoptosis and metabolic inhibitors, and emerging epigenetic agents. We also examine the key translational barriers, particularly antigen overlap with normal progenitors, microenvironmental protection, and the need for assay harmonization, while proposing a practical framework for integrating LSC assessment into risk stratification and therapeutic development.